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ORIGINAL STUDY
Prognostic Implication of Lymphovascular Invasion
Detected by Double Immunostaining for D2-40 and
MITF1 in Primary Cutaneous Melanoma
Laurence Feldmeyer, MD, PhD,* Michael Tetzlaff, MD, PhD,* Patricia Fox, MS,†
Priyadharsini Nagarajan, MD, PhD,* Jonathan Curry, MD,* Doina Ivan, MD,*
Carlos A. Torres Cabala, MD,* Victor G. Prieto, MD, PhD,* and Phyu P. Aung, MD, PhD*
Background: Lymphovascular invasion (LVI) is associated
with adverse outcomes in primary cutaneous melanoma (PCM).
Detection of LVI by hematoxylin and eosin staining alone is
0%–6%, but targeting lymphovascular structures increases the
detection rate.
Objective: To examine the prognostic signiﬁcance of LVI detected
by immunostaining for D2-40 and microphthalmia-associated tran-
scription factor 1 (MITF1) in PCM.
Methods: The authors retrospectively analyzed 120 PCM samples.
We compared the LVI detection rates of immunostaining for D2-40
only (22%), double staining for D2-40 and MITF1 (38%), and
hematoxylin and eosin, and examined the association of LVI with
clinicopathologic variables and clinical outcomes.
Results: Immunolabeling with both methods signiﬁcantly increased
the LVI detection rate. Double staining for D2-40 and MITF1 as well
as D2-40–detected LVI was signiﬁcantly associated with increased
Breslow thickness, number of mitoses, and sentinel lymph node
(SLN) metastasis. D2-40–detected LVI was also associated with
ulceration. Although the difference was not signiﬁcant, double stain-
ing for D2-40 and MITF1 allowed for easier detection of LVI than
D2-40 alone.
Limitations: This study was conducted in a tertiary referral
institution; therefore, a referral bias cannot be excluded.
Conclusions: Immunolabeling increased detection of LVI in
PCM. Because LVI is a positive predictive marker for SLN
metastasis, the authors propose using anti-D2-40 and anti-MITF1
in the evaluation of LVI in patients with PCM with a certain risk of
SLN metastasis.
Key Words: D2-40, immunohistochemistry, lymphovascular inva-
sion, metastasis, MITF1, primary cutaneous melanoma, sentinel
lymph node
(Am J Dermatopathol 2015;0:1–8)
INTRODUCTION
The detection of lymphovascular invasion (LVI) in
primary cutaneous melanoma (PCM) correlates with an
increased risk of relapse, lymph node metastasis, distant
metastases, decreased overall survival (OS), and decreased
disease-free survival (DFS).1 Furthermore, some studies indi-
cate that the prognostic signiﬁcance of LVI could be as strong
as ulceration in predicting relapse and disease-related death in
melanoma.2 However, guidelines from the College of American
Pathologists and the American Joint Committee on Cancer do
not currently consider LVI as a tumor-staging criterion.
The reported incidence of LVI in patients with PCM in
routine hematoxylin and eosin (H&E) slides ranges from 0%
to 6% and is much lower than the reported incidence of
sentinel lymph node (SLN) involvement, which ranges from
17% to 33%, regardless of tumor depth.3–10 This discrepancy
may be due to the difﬁculties associated with accurately iden-
tifying LVI with H&E staining alone, particularly in thick
melanomas, where tumoral occlusion of vascular lumina
can preclude LVI identiﬁcation. Also, immunohistochemical
staining is routinely used for SLN evaluation but not for LVI.
Several studies have shown that immunodetection of
endothelial cells can increase LVI detection.11–13 One such
monoclonal antibody is anti-D2-40, which reacts primarily
with podoplanin and is expressed primarily on lymphatic
endothelium. Anti-D2-40 has been shown to facilitate the
detection of LVI in various malignant tumors, including mel-
anoma.12 In a previous study, we compared detection of LVI
using double immunostaining for D2-40 and S100 versus
H&E staining in 101 PCM samples. The D2-40/S100 immu-
nostaining method increased the LVI detection rate by
approximately 10 times.14 However, clinical follow-up data
for those cases were not available.
The melanoma marker microphthalmia-associated tran-
scription factor 1 (MITF1) exclusively stains the nucleus,
which is easier to interpret, whereas S100 stains both the
nucleus and cytoplasm (and is also less speciﬁc).15 MITF1 is
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almost as sensitive as S100 for detecting conventional mela-
noma cells but has several advantages in the context of a dou-
ble stain: (1) it is more speciﬁc than S100 in the context of
LVI evaluation because S100 is known to highlight other
types of cells in skin including dendritic cells, and (2) MITF1
is a nuclear stain, which allows easier interpretation together
with a cytoplasmic stain like D2-40 than S100, which shows
both nuclear and cytoplasmic positivity in melanoma. How-
ever, MITF1 may highlight other cell types (eg, histiocytes).
To avoid this potential pitfall in our interpretation, we used
other melanocytic markers [melanoma cocktail (MART1 +
tyrosinase + HMB45) and/or SOX10] to conﬁrm the cells,
which were staining with MITF1 in our double (D2-40/
MITF1)-stained slides in this study. Therefore, double stain-
ing for D2-40/MITF1 could be useful to facilitate more accu-
rate histopathological reading of PCM lesions.
In our practice, we routinely immunostain for either
D2-40 only or both D2-40 and MITF1 to detect LVI in PCM
samples for prognostic purposes. In this study, we examined
the prognostic value of LVI detection by immunostaining for
D2-40 and/or MITF1 in PCM. We compared the immuno-
histochemical detection of LVI in PCM with either D2-40
alone or with the double staining method (D2-40/MITF1) to
H&E staining, and we assessed the ability of LVI detected by
these methods to predict SLN status and survival.
METHODS
We retrospectively reviewed the electronic medical
records, surgical reports, and pathology slides of PCM
specimens obtained from patients evaluated at The University
of Texas MD Anderson Cancer Center (UT-MDACC)
between 2010 and 2014. Inclusion criteria were a diagnosis
of PCM and availability of surgical specimens that had been
immunostained with D2-40 or double staining for D2-40 and
MITF1 during diagnostic evaluation. Most of the cases also
had SLN biopsy specimens as the main reason for referral of
the patients with PCM without metastasis to UT-MDACC
was for wide local excision and SLN biopsy. As our practice
has used double staining for D2-40 and MITF1 since April
2012, the follow-up period for this group of patients was
shorter than for the D2-40 group (starting in April 2009).
Patients were separated into 2 groups, those with primary
tumor specimens stained for only D2-40 during diagnostic
evaluation (early in the study period; n = 64) and those who
had double staining for D2-40/MITF1-stained specimens
(later in the study period; n = 56). All patients (n = 120) also
had H&E-stained slides available for review. Data from these
groups were used to assess associations between staining re-
sults, clinicopathologic variables, and outcomes.
To assess the ability of the 2 immunostaining techni-
ques to predict SLN metastasis, we identiﬁed the patients who
had a known SLN status from the 2 groups (48 double
staining for D2-40/MITF1 patients and 41 D2-40 patients).
As the 2 types of D2-40 immunostaining (D2-40 only and
double staining for D2-40/MITF1) were used for different
sets of patients, we performed 1:1 matching between the
double staining for D2-40/MITF1 and D2-40 only groups on
the basis of ethnicity (white vs. other); primary tumor site
(head and neck, extremity, or trunk); and ulceration status.
Matching was performed to account for estimating the
staining effect in the absence of randomization. We were
able to match 26 patients in each group. Propensity scores
were calculated to determine the probability of being in the
D2-40 only or double staining for D2-40/MITF1 groups
based on these variables using logistic regression. The effect
of D2-40 only versus double staining for D2-40/MITF1 was
assessed in the matched pairs using conditional logistic
regression to predict the odds of positive SLN.
To directly compare the ability of the 2 immunostaining
methods to detect LVI, we performed the double staining for
D2-40/MITF1 technique retroactively by adding the MITF1
staining on the slides of 50 patients who initially had only
D2-40 staining (slides were unavailable for the other 14
patients; for those, we used whole slides scanning image for
review of D2-40 stain). Two of 50 slides were technically
equivocal and were excluded from further evaluation. These 48
cases were examined in a blinded and randomized fashion (ie,
without knowledge of the original D2-40 only results).
Samples that already had D2-40/MITF1 stains could not be
stained retroactively with D2-40.
We reviewed the H&E, D2-40, and double staining for
D2-40/MITF1 slides when available and collected the histo-
logical ﬁndings and immunohistochemical results reported at
the time of diagnosis.
From the electronic medical and surgical reports, we
extracted data on patient demographics, the primary tumor site,
and Clark level; Breslow thickness, growth pattern (radial
growth phase or vertical growth phase), mitotic ﬁgures, and
ulceration and width of any ulcers; regression, LVI (detected
through H&E staining, immunostaining for D2-40, or double
staining for D2-40/MITF1), perineural invasion, microsatellite
lesions, mutational status (BRAF, KRAS, and c-KIT), SLN
biopsy and lymphadenectomy results, date and type of recur-
rence [local (ie, on or within 2 cm of the primary melanoma
excision scar), and/or distant metastases], clinical status at the
most recent contact (alive without evidence of recurrence, alive
after recurrence, melanoma-related death, or death caused by
another disease), and follow-up interval.
All patients in this study consented to the institution’s use
of their residual tissue and related medical data for research,
according to the MD Anderson Research Consent Database
(protocol LAB03-0320). This study was approved by the MD
Anderson Institutional Review Board (Protocol # PA14-0711).
Descriptive statistics for baseline characteristics are
provided in percentages. Frequencies and percentages
are provided for categorical variables, and medians (range)
TABLE 1. Comparison of LVI Results From H&E Staining
Versus Double Staining for D2-40 and MITF1 in Tissue Samples
of PCM (n = 56)
H&E LVI
D2-40/MITF1 LVI, n (%)
McNemar PNo Yes
No (n = 55) 34 (62) 21 (38) ,0.0001
Yes (n = 1) 0 1 (100)
Total (n = 56) 34 22
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are provided for continuous variables. Presence of LVI was
compared between staining methods in each group of patients
using McNemar test for paired outcomes. Fisher exact and
Wilcoxon rank-sum tests were used to assess the association
between clinical variables and LVI for each staining method.
All statistical analyses were performed using SAS software
version 9.3. P values are 2-sided and signiﬁcant when less
than 0.05.
RESULTS
We assessed 120 PCM samples for LVI. The tumors
were evaluated through double staining for D2-40/MITF1
(n = 56), D2-40 alone (n = 64), and H&E staining (n = 120).
Immunohistochemistry signiﬁcantly increased the rate of LVI
detection. A signiﬁcant percentage of patients who were LVI
negative according to H&E staining were identiﬁed as LVI
positive when assessed with double staining for D2-40/
MITF1 (21/56, 38%; P , 0.0001) (Table 1 and Fig. 1A) or
D2-40 (13/64, 22%; P = 0.0003) (Table 2 and Fig. 1B).
LVI detected by either double staining for D2-40/
MITF1 or D2-40 alone was associated signiﬁcantly with
increased Breslow thickness (P = 0.02 and P = 0.0002,
respectively) and number of mitoses (P = 0.03 and P =
0.001) (Table 3). Additionally, D2-40–detected LVI was
associated with ulceration (P = 0.0006) and with decreased
incidence of radial growth phase (P = 0.02) (Table 4).
The odds of SLN metastasis in LVI-positive patients
were 5.2 (double staining for D2-40/MITF1) and 26 (D2-40
alone) times greater than in LVI-negative patients (P = 0.01
and P = 0.0003, respectively). We found that SLN metastasis
was associated with LVI detected by either double staining
for D2-40/MITF1 [13 (72%); P = 0.02] or D2-40 immunos-
taining [9 (75%); P = 0.0001] (Tables 5 and 6). We did not
observe a signiﬁcant group effect of the double staining for
D2-40/MITF1 method versus D2-40 immunostaining for the
prediction of SLN metastasis (Table 7).
In the D2-40 only group, 11/64 (17%) patients died.
Thus, the median survival time was not reached because less
than 50% of the patients died. The median follow-up time for
that group was 24.6 months (range, 0.3–58.2). We did not
observe a signiﬁcant association between D2-40–detected
LVI and OS. Because only 1 patient died in the double staining
for D2-40/MITF1 group, we did not perform a survival anal-
ysis for that cohort. The median follow-up time for the double
staining for D2-40/MITF1 group was 3.1 months (range, 1.0–
24.3). We did not observe a signiﬁcant difference between
double staining for D2-40/MITF1 and D2-40 immunostaining
in LVI detection when the 2 techniques were compared directly
(P = 0.4795). However, double staining for D2-40/MITF1
identiﬁed 5 LVI-positive patients missed by D2-40 alone,
whereas D2-40 identiﬁed 3 LVI patients that double staining
for D2-40/MITF1 showed to be LVI negative (the intravascular
cells possibly were nonmelanoma cells or were melanoma cells
that did not express MITF1). The LVI detection rates for D2-
40 only and double staining for D2-40/MITF1 were 23% and
27%, respectively (Fisher exact P value, P = 0.814).
DISCUSSION
Our study’s main objectives were to identify the histo-
logical and clinical parameters associated with LVI and to
determine whether double staining for D2-40/MITF1 offered
an advantage compared with D2-40 only staining.
LVI Detection
Our ﬁndings conﬁrm the results of several studies
demonstrating that immunohistochemistry for D2-40 increased
FIGURE 1. A, Representative photo-
micrographs of a PCM tissue sample
with LVI revealed by D2-40 (brown
chromogen). B, Representative pho-
tomicrograph of a PCM tissue sample
with LVI detected by double staining
(D2-40; red chromogen and MITF1;
brown chromogen).
TABLE 2. Comparison of LVI Results From H&E Staining
Versus Immunostaining for D2-40 Alone in Tissue Samples of
PCM (n = 64)
H&E LVI
D2-40 Only LVI, n (%)
McNemar PNo Yes
No (n = 60) 47 (78) 13 (22) 0.0003
Yes (n = 4) 0 4 (100)
Total (n = 64) 47 17
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TABLE 3. Association of Clinicopathologic Variables With LVI Detected By Double Staining for D2-40 and MITF1 and LVI Detected
by H&E Staining in Patients With PCM (n = 56)
Variable
H&E LVI, n (%)* D2-40/MITF1 LVI, n (%)*
No (n = 55) Yes (n = 1) P† No (n = 34) Yes (n = 22) P
Sex
Female 19 (100) 0 NA 12 (63) 7 (37) 0.7885
Male 36 (97) 1 (3) NA 22 (60) 15 (41)
Ethnicity
Asian 1 (50) 1 (50) NA 1 (50) 1 (50) 0.6226
White 51 (100) 0 NA 32 (63) 19 (37)
Hispanic 3 (100) 0 NA 1 (33) 2 (67)
Primary site
Head/neck 13 (100) 0 NA 9 (69) 4 (31) 0.2760
Lower extr. 11 (92) 1 (8) NA 6 (50) 6 (50)
Trunk 19 (100) 0 NA 14 (74) 5 (26)
Upper extr. 12 (100) 0 NA 5 (42) 7 (58)
Clark level
4 51 (100) 0 NA 31 (61) 20 (39) 1.000
5 4 (80) 1 (20) NA 3 (60) 2 (40)
RGP
Absent 30 (97) 1 (3) NA 17 (55) 14 (45) 0.3161
Present 25 (100) 0 NA 17 (68) 8 (32)
VGP
Absent 2 (100) 0 NA 2 (100) 0 0.5143
Present 53 (98.1) 1 (1.9) NA 32 (59) 22 (41)
Ulceration
Absent 21 (95.5) 1 (4.5) NA 13 (59) 9 (41) 0.8414
Present 34 (100) 0 NA 21 (62) 13 (38)
Regression
Absent 48 (98) 1 (2) NA 31 (63) 18 (37) 0.4149
Present 7 (100) 0 NA 3 (43) 4 (57)
PNI
Absent 49 (100) 0 NA 31 (63) 18 (37) 0.4149
Present 6 (86) 1 (14) NA 3 (43) 4 (57)
Micro_Sat
Absent 53 (100) 0 NA 33 (62) 20 (38) 0.5548
Present 2 (67) 1 (33) NA 1 (33) 2 (67)
BRAF
Missing 36 (100) 0 NA 24 (67) 12 (33) 1.000
WT 10 (91) 1 (9) NA 7 (64) 4 (36)
Mut 9 (100) 0 NA 5 (56) 4 (44)
KIT
Missing 37 (100) 0 NA 25 (67) 12 (33) 0.7014
WT 17 (94.4) 1 (5.6) NA 12 (67) 6 (33)
Mut 1 (100) 0 NA 0 1 (100)
KRAS
Missing 38 (100) 0 NA 25 (67) 13 (33) 0.3285
WT 14 (100) 0 NA 8 (57) 6 (43)
Mut 4 (100) 0 NA 4 (100) 0
Age, median (range), yrs 63 (21–87) 62 (62-62) NA 64 (31–87) 62 (21–86) 0.4553
Breslow, median (range), mm 3.2 (0.7–12) 7.8 (7.8–7.8) NA 2.9 (0.7–12.0) 4.0 (1.3–10.2) 0.0199
Mitotic ﬁgures, median (range), mm2 10 (1–35) 12 (12-12) NA 8.5 (1–35) 15 (2–33) 0.0322
Ulcer width, median (range), mm2 5.3 (0.2–28) NA NA 4.0 (0.2–23) 6.0 (0.5–28) 0.1260
*Unless otherwise indicated.
†P values for H&E are not useful with only 1 patient testing positive on H&E.
BRAF, B-Raf proto-oncogene, serine/threonine kinase; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; extr., extremity; KRAS, V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog; Micro_Sat, microsatellite lesions; Mut, mutantated; PNI, perineural invasion; RGP, radial growth phase; VGP, vertical growth phase; WT, wild type.
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TABLE 4. Association With Clinicopathologic Variables With LVI Detected By Immunostaining for D2-40 Alone and LVI Detected
by H&E Staining in Patients With PCM (n = 64)
Variable
H&E LVI, n (%)* D2-40 Only LVI, n (%)*
No (n = 60) Yes (n = 4) P No (n = 47) Yes (n = 17) P
Sex
Female 16 (89) 2 (11) 0.3131 12 (67) 6 (33) 0.4430
Male 44 (96) 2 (4) 35 (76) 11 (24)
Ethnicity
Asian 1 (100) 0 0.3783 0 1 (100) 0.3690
White 1 (100) 0 1 (100) 0
Hispanic 54 (95) 3 (5) 43 (75) 14 (25)
4 (80) 1 (20) 3 (60) 2 (40)
Primary site
Head/neck 22 (96) 1 (4) 0.4151 16 (70) 7 (30) 0.2073
Lower extr. 9 (82) 2 (18) 6 (55) 5 (45)
Trunk 17 (94) 1 (6) 16 (89) 2 (11)
Upper extr. 12 (100) 0 9 (75) 3 (25)
Clark level
2 4 (100) 0 1.000 4 (100) 0 0.7962
3 4 (100) 0 3 (75) 1 (25)
4 41 (93) 3 (7) 32 (73) 12 (27)
5 11 (92) 1 (8) 8 (67) 4 (33)
RGP
Absent 12 (92) 1 (8) 0.0901 8 (61) 5 (39) 0.0171
Not evaluable 9 (82) 2 (18) 5 (45) 6 (55)
Present 39 (97) 1 (3) 34 (85) 6 (15)
VGP
Absent 5 (100) 0 1.000 5 (100) 0 0.3131
Present 55 (93) 4 (7) 42 (71) 17 (29)
Ulceration
Absent 51 (98) 1 (2) 0.0188 43 (83) 9 (17) 0.0006
Not evaluable 1 (100) 0 1 (100) 0
Present 8 (73) 3 (27) 3 (27) 8 (73)
Regression
Absent 35 (95) 2 (5) 1.000 25 (68) 12 (32) 0.2609
Present 25 (93) 2 (7) 22 (81) 5 (19)
PNI
Absent 48 (94) 3 (6) 1.000 38 (74) 13 (26) 0.7320
Present 12 (92) 1 (8) 9 (69.2) 4 (31)
Micro_Sat
Absent 59 (95) 3 (4.8) 0.1220 46 (74.2) 16 (26) 0.4638
Present 1 (50) 1 (50) 1 (50) 1 (50)
BRAF
Missing 47 (94) 3 (6) 0.6375 39 (78) 11 (22) 0.1667
WT 10 (91) 1 (9) 6 (54) 5 (46)
Mut 3 (100) 0 2 (67) 1 (33)
KIT
Missing 52 (94) 3 (6) 0.4632 43 (78) 12 (22) 0.0734
WT 5 (83) 1 (17) 3 (50) 3 (50)
Mut 3 (100) 0 1 (33.3) 2 (66.7)
KRAS
Missing 53 (94.6) 3 (5.4) 0.0656 42 (75) 14 (25) 0.3939
WT 7 (100) 0 5 (71) 2 (29)
Mut 0 1 (100) 0 1 (100)
Age, median (range), yrs 67 (28–96) 49 (36–83) 0.1972 64 (28–95) 75 (36–96) 0.2607
(continued on next page )
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the frequency of LVI detection in PCM compared with
conventional H&E staining. Niakosari et al12 found that
D2-40 immunohistochemistry identiﬁed LVI in 16% of 44
melanoma samples, while H&E staining failed to detect any
cases with LVI. Fohn et al16 showed that D2-40 immunohis-
tochemistry increased the LVI detection rate to 22% (from 3%
using only H&E staining). Xu et al17 showed that H&E alone
detected LVI in 5 (5%) of 106 PCM, whereas dual immunos-
taining for podoplanin and S-100 and multispectral imaging
analysis identiﬁed LVI in 35 patients (33%). Rose et al11 as-
sessed 246 primary melanomas for LVI using D2-40 immu-
nostaining, CD34 immunostaining, and routine histology, and
found that the use of endothelial markers increased the LVI
detection rate (D2-40 and/or CD34, 18%, vs. routine histology,
3%). In another study, D2-40/S-100 dual immunostaining iden-
tiﬁed LVI in 10 of 27 PCM, whereas routine histology identi-
ﬁed only 1 patient.10 Using immunostaining for D2-40,
Peterson et al found LVI in 23% of 74 invasive melanomas.9
Our double staining for D2-40/MITF1 method showed the
highest LVI detection rate to date (38%). Taken together, these
ﬁndings conﬁrm that LVI is underestimated by H&E alone,
and that immunohistochemistry is an essential ancillary diag-
nostic tool for LVI.
We observed that LVI detected by both double staining
for D2-40/MITF1 or D2-40 alone was signiﬁcantly associated
with increased Breslow thickness and number of mitoses.
Furthermore, LVI detected by D2-40 alone was also signif-
icantly associated with ulceration. Niakosari et al12 also
observed a trend toward an association between LVI and
a deeper Clark level and increased frequency of ulceration.
In a later study from the same group, D2-40–detected LVI
was signiﬁcantly associated with a deeper Clark level of inva-
sion and greater Breslow tumor thickness.13 Rose et al11
found that D2-40–detected or CD34-detected LVI was
signiﬁcantly associated with more adverse clinicopathologic
variables (thickness, ulceration, mitoses, and nodular sub-
type) compared with LVI detected by routine histology (only
thickness and ulceration). Taken together, these results con-
ﬁrm the association between immunohistochemical detection
of LVI using D2-40 with Breslow thickness, mitosis, and
ulceration—3 essential prognostic parameters.
SLN Status
Our results showed an association between D2-40–
detected LVI and positive SLN status, which supports the
ﬁndings of recent studies. Niakosari et al13 identiﬁed SLN
metastasis in 23 (24%) of 96 cases compared with 69%
(double staining for D2-40/MITF1) and 29% (D2-40 only)
in our series. Through multivariate analysis, Niakosari
et al13 also found that D2-40–detected LVI, younger age,
and ulceration were independent prognostic factors for SLN
metastasis. Fohn et al16 showed that D2-40–detected LVI
was the most signiﬁcant predictor of SLN metastasis,
whereas Doeden et al18 showed that a combination of LVI
and intratumoral lymphatics had higher positive and negative
predictive values for the risk of developing SLN metastasis
compared with routine histology and LVI. However, Petitt
et al19 showed no association between LVI and SLN status:
8 of 10 melanomas with LVI were SLN-negative, possibly
owing to the small patient sample. Our results conﬁrm that
LVI is a signiﬁcant predictor of SLN metastases and can iden-
tify patients with a low risk of SLN metastasis who might be
spared from invasive SLN biopsy.
Survival Outcomes
Several previous studies showed an association between
LVI and distant metastasis, OS, and DFS in patients with
PCM.1,11,17 Previously, we showed that OS and disease-speciﬁc
TABLE 4. (Continued ) Association With Clinicopathologic Variables With LVI Detected By Immunostaining for D2-40 Alone and LVI
Detected by H&E Staining in Patients With PCM (n = 64)
Variable
H&E LVI, n (%)* D2-40 Only LVI, n (%)*
No (n = 60) Yes (n = 4) P No (n = 47) Yes (n = 17) P
Breslow, median (range), mm 1.8 (0.2–29) 4.8 (2.5–5.5) 0.0690 1.3 (0.2–29) 4.8 (0.9–21) 0.0002
Mitotic ﬁgures, median (range), mm2 2 (0–55) 5 (2–14) 0.1983 1 (0–55) 6 (2–20) 0.0010
Ulcer width, median (range), mm 9 (0.3–21) 3.0 (1.8–13.0) 0.5676 11 (3–21) 6.5 (0.3–20) 0.4236
*Unless otherwise indicated.
BRAF, B-Raf proto-oncogene, serine/threonine kinase; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog; Micro_Sat, microscopic metastasis; Mut, mutantated; PNI, perineural invasion; RGP, radial growth phase; VGP, vertical growth phase; WT, wild type.
TABLE 5. Association Between LVI Detected By Double




Fisher Exact PNo Yes
No (n = 30) 20 (67) 10 (33) 0.0162
Yes (n = 18) 5 (28) 13 (72)
Total (n = 48) 25 33
TABLE 6. Association Between LVI Detected By
Immunostaining for D2-40 Alone and SLN Metastasis
D2-40 Only LVI
Sentinel Lymph Node Metastasis,
n (%)
Fisher Exact PNo Yes
No (n = 29) 26 (90) 3 (10) 0.0001
Yes (n = 12) 3 (25) 9 (75)
Total (n = 41) 29 12
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survival durations were shorter for patients with LVI than for
those without LVI, and that immunostaining-detected LVI and
ulceration were associated signiﬁcantly with OS.9 Rose et al11
found that immunostaining-detected LVI was a signiﬁcant
marker of both reduced DFS and OS. Xu et al17 found that
LVI was associated signiﬁcantly with time to regional nodal
metastatic disease, time to ﬁrst metastasis, and melanoma-
speciﬁc death.
In this study, we did not observe a signiﬁcant associ-
ation between D2-40–detected LVI and OS or recurrence.
Additionally, neither D2-40–detected nor double staining
for D2-40/MITF1-detected LVI was signiﬁcantly associated
with clinical outcomes, including regional nodal metastasis or
satellite/local/distant metastasis. This ﬁnding might be due to
the short follow-up period; during the maximum 4-year
follow-up period in our study, only 11 (17%) of the 64 pa-
tients died.
Comparison Between D2-40 Only and Double
Staining for D2-40/MITF1
When comparing the 26 matched patients, we did not
observe a signiﬁcant difference in the prediction of SLN
metastasis (Table 7). When comparing D2-40 immunostain-
ing and double staining for D2-40/MITF1 for patients who
had both stains, we did not observe a signiﬁcant difference in
the LVI detection rates (P value = 0.47, n = 48). However,
our double staining for D2-40/MITF1 method identiﬁed LVI
in an additional 5 patients not identiﬁed by immunostaining
for only D2-40. D2-40 immunostaining resulted in a false-
positive LVI diagnosis for 3 patients (Fig. 1C); the double
staining for D2-40/MITF1 method showed that the intravas-
cular cells in these samples were not melanocytes (or, less
likely, melanocytes that did not express MITF1 because none
of these patients showed SLN metastasis and primary mela-
noma in these cases stained positively for MITF1) (Fig. 1D).
Limitations
This retrospective study was conducted at a single
institution; therefore, misclassiﬁcation and referral bias
cannot be excluded. Also the shorter clinical follow-up,
especially in the group with double staining for D2-40 and
MITF1 is also one of the limitations. Nevertheless, the large
sample size of our study and the collection of data based on
electronic medical and surgical reports offer reliable infor-
mation. No multivariate analysis was performed in this study
to investigate if LVI is an independent prognostic marker in
patients with PCM.
CONCLUSIONS
In summary, our results indicate that immunostaining
with D2-40 and with double staining for D2-40/MITF1
increased the LVI detection rates in patients with PCM, and
that LVI is associated signiﬁcantly with known adverse
clinicopathologic parameters. Although we did not observe
a signiﬁcant difference in LVI detection between the single
immunostaining and the double staining for D2-40/MITF1
methods, double staining for D2-40/MITF1 might offer
higher sensitivity and speciﬁcity than immunostaining for
only D2-40. Because LVI is a positive predictive marker for
SLN metastasis, we propose the use of immunohistochemical
study for the evaluation of LVI in patients with PCM with
a risk of SLN metastasis.
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